Andrew Wilson, MSN

US Medical Director, Hemophilia
Sanofi

Poster(s):

• (224) Real-world experience with efanesoctocog alfa in patients with moderate and severe hemophilia A: Final analysis of the Adelphi hemophilia wave III disease specific programmeTM
  Wednesday, October 29, 2025